Discovery

Scipher Medicine

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

Scipher Medicine and Galapagos Sign Collaboration in Inflammatory Bowel Disease

Lead Product(s): Undisclosed

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Galapagos

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 12, 2020

Details:

Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by Scipher after which Galapagos has the exclusive option to progress up to five targets into further drug discovery and development.

Celsius Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflammatory Bowel Disease Biology

Lead Product(s): Undisclosed

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: University of Oxford

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 01, 2020

Details:

Celsius will partner with leading academic scientists to access patient tissue samples and apply its proprietary single-cell genomics platform and machine learning capabilities to discover new insights into inflammatory bowel disease (IBD).

Second Genome

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery

Lead Product(s): Undisclosed

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Gilead Sciences

Deal Size: $1,538.0 million Upfront Cash: $38.0 million

Deal Type: Collaboration April 06, 2020

Details:

Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines.